|
|
Volumn 27, Issue 1, 2009, Pages 6-8
|
|
Buzz around Campath proof-of-concept trial in MS
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
4 AMINOPYRIDINE;
ALEMTUZUMAB;
BETA1A INTERFERON;
CLADRIBINE;
CYCLOPHOSPHAMIDE;
DIRUCOTIDE;
FINGOLIMOD;
FUMARIC ACID DIMETHYL ESTER;
LAQUINIMOD;
MYELIN BASIC PROTEIN[82-98];
REVIMMUNE;
RITUXIMAB;
TERIFLUNOMIDE;
UNCLASSIFIED DRUG;
B LYMPHOCYTE;
CHRONIC LYMPHATIC LEUKEMIA;
CLINICAL TRIAL;
GRAFT VERSUS HOST REACTION;
HUMAN;
IMMUNE SYSTEM;
MULTIPLE SCLEROSIS;
NOTE;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PRIORITY JOURNAL;
RELAPSE;
T LYMPHOCYTE;
ANIMALS;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, NEOPLASM;
ANTINEOPLASTIC AGENTS;
BRAIN;
CLINICAL TRIALS AS TOPIC;
HUMANS;
IMMUNOTHERAPY;
MAGNETIC RESONANCE IMAGING;
MULTIPLE SCLEROSIS;
RATS;
TREATMENT OUTCOME;
|
|
EID: 60149087275
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0109-6 Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|
